Edgewise Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1715 38th St, Boulder, Colorado, 80301, ...Phone Number
(720) 262-7002Website
www.edgewisetx.comRevenue
$24.7 MillionStock Symbol
EWTXIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
4
3
1
2
2
About Edgewise Therapeutics
EDGEWISE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. EDGEWISE has combined its expertise in muscle biology and small molecule engineering to build a proprietary, muscle focused drug discovery platform. The platform utilizes custom-built systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company is based in Boulder, CO.Explore more
Edgewise Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Edgewise Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Edgewise Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Edgewise Therapeutics recently announced quarterly report
Check if Edgewise Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Edgewise Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Edgewise Therapeutics
Check out if Edgewise Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Edgewise Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Edgewise Therapeutics launches new products
Recommended Actions
Find VP level buyers at Edgewise Therapeutics
Find more new buyers
Compare Similar Companies to Edgewise Therapeutics
Compare insights from companies similar to Edgewise Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Edgewise Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Edgewise Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Edgewise Therapeutics.
Edgewise Therapeutics financials insights
Gather financial insights about Edgewise Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$15.5M
2019
Series B
$50M
2020
Series C
$95M
2021
Stock Offering
$202.4M
Edgewise Therapeutics Tech Stack
A closer look at the technologies used by Edgewise Therapeutics
Most Recent Scoops
Person-Based
Events
Person-Based
Pharmaceuticals, Business Finance, Finance
Hiring Plans
Edgewise Therapeutics has more open roles in Medical & Health than it has had at any time in the past 6 months with an increased focus that include Biotechnology, Pharmaceutical Manufacturing, and Biophysics, and experience with Molecular Biology, Clinical System Operations, Protein Purification, and ICH Guidelines.
Hiring Plans
Person-Based
Events
Person-Based
Events
Edgewise Therapeutics News & Media
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential...Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June...Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500...Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29,...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Edgewise Therapeutics
Sign Up For FreeTo access detailed company insights
EDGEWISE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. EDGEWISE has combined its expertise in muscle biology and small molecule engineering to build a proprietary, muscle focused drug discovery platform. The platform... Read More
